VTN and neoplasm: As suggested by Gunn and co-workers [57], differing levels of tumor-derived complement proteins could contribute to observed differences in immune responses to the tumor, with low C5a levels inhibiting tumor growth by promoting Th1 cell differentiation, and high levels promoting Treg differentiation and stimulating tumor growth.